Injectables
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
Mallinckrodt, Endo set for $6.7B merger
pharmaceutical merger, opioid litigation, generics, injectables, synergies
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
Uzedy, Teva, and MedinCell’s Collaborative Effort Yields Success in Phase 3 Trials for Long-Acting Schizophrenia Treatment
Uzedy, Teva, MedinCell, long-acting, schizophrenia, phase 3 trials, treatment, collaboration, mental health, neuroscience, psychiatry, injectable medication.
Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma
Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.